From: Impact of self-reported Gastroesophageal reflux disease in subjects from COPDGene cohort
 | Model 1 GERD diagnosis Regression coefficient or OR (95% CI) | Model 2 Additionally adjusted for propensity to be diagnosed with GERD Regression coefficient or OR (95% CI) | Model 3 Additionally adjusted for PPIs use and GERD-PPIs Interaction Regression coefficient or OR (95% CI) |
---|---|---|---|
Outcome: SGRQ score symptoms | |||
GERD | 7.40 (5.93, 8.87) | 2.48 (1.01, 3.95) | 3.40 (1.56, 5.22) |
PPI use | Â | Â | 4.19 (1.09, 7.28) |
GERD*PPIs interaction (p-value) | Â | Â | 0.006 |
Outcome: SGRQ score activity | |||
GERD | 6.35 (4.83, 7.81) | 3.00 (1.46, 4.55) | 3.82 (1.90, 5.75) |
PPI use | Â | Â | 3.63 (0.37, 6.88) |
GERD*PPIs interaction (p-value) | Â | Â | 0.021 |
Outcome: SGRQ score impact | |||
GERD | 5.48 (4.27, 6.69) | 2.34 (1.10, 3.58) | 3.09 (1.55, 4.64) |
PPI use | Â | Â | 3.75 (1.14, 6.36) |
GERD*PPIs Interaction (p-value) | Â | Â | 0.005 |
Outcome: SGRQ total score | |||
GERD | 6.05 (4.85, 7.26) | 2.58 (1.36, 3.80) | 3.38 (1.86, 4.90) |
PPI use | Â | Â | 3.77 (1.19, 6.34) |
GERD*PPIs interaction (p-value) | Â | Â | 0.003 |
Outcome: Count of exacerbations in the year prior to enrollment** | |||
GERD | 1.32 (1.21, 1.44) | 1.16 (1.06, 1.27) | 1.17 (1.05, 1.31) |
PPI use | Â | Â | 1.20 (1.00, 1.44) |
GERD*PPIs interaction | Â | Â | NS |
Outcome: Frequent exacerbator at enrollment | |||
GERD | 1.88 (1.57, 2.24) | 1.41 (1.17, 1.71) | 1.40 (1.10, 1.77) |
PPI use | Â | Â | 1.60 (1.09, 2.35) |
GERD*PPIs interaction | Â | Â | NS |
Outcome: Frequent exacerbator at follow-up | |||
GERD | 1.81 (1.52, 2.16) | 1.50 (1.24, 1.82) | 1.40 (1.10, 1.79) |
PPI Use | Â | Â | 1.56 (1.06, 2.30) |
GERD*PPIs interaction | Â | Â | NS |